Free Trial

iCAD Q3 2023 Earnings Report

iCAD logo
$2.70 -0.13 (-4.59%)
As of 02/21/2025 04:00 PM Eastern

iCAD EPS Results

Actual EPS
-$0.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

iCAD Revenue Results

Actual Revenue
$4.07 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

iCAD Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

iCAD Earnings Headlines

StockNews.com Upgrades iCAD (NASDAQ:ICAD) to "Hold"
iCAD, Inc. (ICAD): A Bull Case Theory
Bill Gates’ is about to mint millionaires (again) with Stargate.
This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.
iCAD Shares Unchanged Ahead of Presentations
See More iCAD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iCAD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iCAD and other key companies, straight to your email.

About iCAD

iCAD (NASDAQ:ICAD) engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

View iCAD Profile

More Earnings Resources from MarketBeat